{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:20:43Z","timestamp":1793409643725,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40123-025-01137-8","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T13:46:22Z","timestamp":1744811182000},"page":"1337-1347","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Structural and Functional Insight into Intracameral Cefuroxime Ocular Toxic Syndrome (ICOTS) in Eyes with Disrupted Intraocular Barrier"],"prefix":"10.1007","volume":"14","author":[{"given":"Andrea","family":"Cusumano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"Pileri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Falsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Cesareo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"D\u2019Apolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3874-8327","authenticated-orcid":false,"given":"Marco","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"1137_CR1","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jcrs.2007.02.032","volume":"33","author":"Endophthalmitis Study Group, European Society of Cataract & Refractive Surgeons","year":"2007","unstructured":"Endophthalmitis Study Group, European Society of Cataract & Refractive Surgeons. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 2007;33:978\u201388.","journal-title":"J Cataract Refract Surg."},{"key":"1137_CR2","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1001\/jamaophthalmol.2024.1716","volume":"142","author":"J Van Rooij","year":"2024","unstructured":"Van Rooij J, Nolte K, Van De Vondervoort F, Lekkerkerk S, Bourgonje V, Wubbels R. Prophylactic intracameral antibiotics and endophthalmitis after cataract surgery. JAMA Ophthalmol. 2024;142:699.","journal-title":"JAMA Ophthalmol"},{"key":"1137_CR3","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamaophthalmol.2024.2210","volume":"142","author":"V Daien","year":"2024","unstructured":"Daien V, Villain M, Chamard C. Intracameral antibiotics after cataract surgery\u2014in which cases? JAMA Ophthalmol. 2024;142:706.","journal-title":"JAMA Ophthalmol"},{"key":"1137_CR4","doi-asserted-by":"publisher","unstructured":"Schwartz S, Grzybowski A, Flynn H. Antibiotic prophylaxis: different practice patterns within and outside the United States. Clin Ophthalmol. 2016;10:251\u20136. https:\/\/doi.org\/10.2147\/OPTH.S100429.","DOI":"10.2147\/OPTH.S100429"},{"key":"1137_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/ICU.0000000000001101","volume":"36","author":"YA Fouad","year":"2025","unstructured":"Fouad YA, Karimaghaei S, Elhusseiny AM, Alagorie AR, Brown AD, Sallam AB. Pseudophakic cystoid macular edema. Curr Opin Ophthalmol. 2025;36:62\u20139.","journal-title":"Curr Opin Ophthalmol"},{"key":"1137_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101557","volume":"26","author":"A Raharja","year":"2022","unstructured":"Raharja A, Neffendorf JE, Williamson TH. Retinal toxicity secondary to subconjunctival cefuroxime following pars plana vitrectomy: a case report and literature review. Am J Ophthalmol Case Rep. 2022;26:101557.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"1137_CR7","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ajo.2013.10.018","volume":"157","author":"S \u00c7ift\u00e7i","year":"2014","unstructured":"\u00c7ift\u00e7i S, \u00c7ift\u00e7i L, Da\u011f U. Hemorrhagic retinal infarction due to inadvertent overdose of cefuroxime in cases of complicated cataract surgery: retrospective case series. Am J Ophthalmol. 2014;157:421-5.e2.","journal-title":"Am J Ophthalmol"},{"key":"1137_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4274\/tjo.61580","volume":"48","author":"S S\u00fcl","year":"2018","unstructured":"S\u00fcl S, Karalezli A. Development of retinal infarct due to intracameral cefuroxime injection following complicated cataract surgery. Turk J Ophthalmol. 2018;48:317\u20139.","journal-title":"Turk J Ophthalmol"},{"key":"1137_CR9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.oret.2022.02.007","volume":"6","author":"MR Munk","year":"2022","unstructured":"Munk MR, Kashani AH, Tadayoni R, et al. Recommendations for OCT angiography reporting in retinal vascular disease. Ophthalmol Retin. 2022;6:753\u201361.","journal-title":"Ophthalmol Retin"},{"key":"1137_CR10","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.jcrs.2011.03.032","volume":"37","author":"F Qureshi","year":"2011","unstructured":"Qureshi F, Clark D. Macular infarction after inadvertent intracameral cefuroxime. J Cataract Refract Surg. 2011;37:1168\u20139.","journal-title":"J Cataract Refract Surg"},{"key":"1137_CR11","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1001\/jamaophthalmol.2015.2421","volume":"133","author":"DC Wong","year":"2015","unstructured":"Wong DC, Waxman MD, Herrinton LJ, Shorstein NH. Transient macular edema after intracameral injection of a moderately elevated dose of cefuroxime during phacoemulsification surgery. JAMA Ophthalmol. 2015;133:1194.","journal-title":"JAMA Ophthalmol"},{"key":"1137_CR12","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1016\/j.jcjo.2016.05.008","volume":"51","author":"M Aslankurt","year":"2016","unstructured":"Aslankurt M, \u00c7eki\u00e7 O, And\u0131 \u0130, Dursun O. Transient macular edema after standard dose of intracameral cefuroxime injection during phacoemulsification. Can J Ophthalmol. 2016;51:e141\u20132.","journal-title":"Can J Ophthalmol"},{"key":"1137_CR13","doi-asserted-by":"publisher","unstructured":"Lam Philip TH, Young C, Tam L. Randomized controlled trial on the safety of intracameral cephalosporins in cataract surgery. Clin Ophthalmol. 2010;2010:1499\u20141504. https:\/\/doi.org\/10.2147\/OPTH.S15602.","DOI":"10.2147\/OPTH.S15602"},{"key":"1137_CR14","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1001\/jamaophthalmol.2016.1351","volume":"134","author":"V Daien","year":"2016","unstructured":"Daien V, Papinaud L, Gillies MC, et al. Effectiveness and safety of an intracameral injection of cefuroxime for the prevention of endophthalmitis after cataract surgery with or without perioperative capsular rupture. JAMA Ophthalmol. 2016;134:810.","journal-title":"JAMA Ophthalmol"},{"key":"1137_CR15","unstructured":"The Royal College of Ophthalmologists. Ophthalmic safety alert\u2013intracameral cefuroxime. https:\/\/www.rcophth.ac.uk\/news-views\/ophthalmic-safety-alert-intracameral-cefuroxime\/. Accessed 18 Mar 2025."},{"key":"1137_CR16","doi-asserted-by":"publisher","first-page":"204209862412580","DOI":"10.1177\/20420986241258049","volume":"15","author":"C Jiang","year":"2024","unstructured":"Jiang C, Zheng X, Li P, Qian J, Li Q. A retrospective pharmacovigilance study of post-marketing safety concerns with cefuroxime. Ther Adv Drug Saf. 2024;15:20420986241258050.","journal-title":"Ther Adv Drug Saf"},{"key":"1137_CR17","doi-asserted-by":"publisher","first-page":"9745","DOI":"10.1038\/s41598-019-46236-2","volume":"9","author":"H Miyake","year":"2019","unstructured":"Miyake H, Miyazaki D, Shimizu Y, et al. Toxicities of and inflammatory responses to moxifloxacin, cefuroxime, and vancomycin on retinal vascular cells. Sci Rep. 2019;9:9745.","journal-title":"Sci Rep"},{"key":"1137_CR18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000526449","volume":"66","author":"J Sun","year":"2023","unstructured":"Sun J, Wei Y, Li H, Zheng S, Wu X. Macular toxicity of low-concentration cefuroxime during cataract surgery in vitrectomized eyes. Ophthalmic Res. 2023;66:116\u201323.","journal-title":"Ophthalmic Res"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01137-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01137-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01137-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T13:07:11Z","timestamp":1747055231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01137-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1137"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01137-8","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrea Cusumano declares that he has no competing interests. Marco Andrea Pileri declares that he has no competing interests. Benedetto Falsini declares that he has no competing interests. Massimo Cesareo declares that he has no competing interests. Michele D\u2019Ambrosio declares that he has no competing interests. Fabian D\u2019Apolito declares that he has no competing interests. Francesco Martelli declares that he has no competing interests. Marco Lombardo declares that he has no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. The study was approved by the Internal Review Board of the University of Tor Vergata (ethics approval ID: 263.22). Written informed consent was obtained from all participants for the use of the data and their publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}